Faruqi & Faruqi Encourages REGENXBIO Investors to Reach Out
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy RGNX?
Source: PRnewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against REGENXBIO, specifically targeting investors who purchased or acquired securities between February 9, 2022, and January 27, 2026, aiming to protect investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to investor advocacy.
- Class Action Reminder: The firm reminds investors that April 14, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against REGENXBIO, emphasizing the importance of timely action.
- Potential Impact Assessment: This legal action could negatively affect REGENXBIO's stock price, prompting investors to monitor developments closely to make informed investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.960
Low
19.00
Averages
29.71
High
45.00
Current: 8.960
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regenxbio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data, leading to significant investor losses once the truth was revealed, indicating a pattern of false and misleading public statements throughout the class period.
- Market Reaction: Following the revelation of concealed negative information, investor losses surged, highlighting the company's major missteps in disclosure practices, which could lead to a trust crisis and impact future financing capabilities.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to join the lawsuit for potential recovery, underscoring the importance of legal avenues in protecting shareholder rights.
See More
REGENXBIO Class Action Lawsuit Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding the development of RGX-111 gene therapy, claiming positive biomarker and safety data while concealing material adverse facts about the therapy's efficacy and safety, resulting in investor losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in the field.
- Investor Selection Advice: The law firm advises investors to choose qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure optimal legal support and representation in the class action.
See More
Faruqi & Faruqi Encourages REGENXBIO Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against REGENXBIO, specifically targeting investors who purchased or acquired securities between February 9, 2022, and January 27, 2026, aiming to protect investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to investor advocacy.
- Class Action Reminder: The firm reminds investors that April 14, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against REGENXBIO, emphasizing the importance of timely action.
- Potential Impact Assessment: This legal action could negatively affect REGENXBIO's stock price, prompting investors to monitor developments closely to make informed investment decisions.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Choosing Legal Counsel: The firm emphasizes the importance of selecting qualified legal representation with a proven track record, noting that many firms issuing notices may lack the necessary experience and resources to effectively handle securities class actions.
- Case Background: The lawsuit alleges that defendants provided misleading information regarding REGENXBIO's RGX-111 gene therapy development, concealing adverse facts about its efficacy and safety, which resulted in investor losses when the truth emerged.
- Historical Achievements: In 2019, Rosen Law Firm secured over $438 million for investors and was ranked first by ISS Securities Class Action Services in 2017 for the number of settlements, showcasing its strong capabilities and influence in the securities litigation field.
See More
Notice of Class Action Lawsuit Against REGENXBIO Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that REGENXBIO misled investors regarding its RGX-111 gene therapy development, providing false and misleading information while claiming positive biomarker and safety data from ongoing Phase I/II studies.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company in 2017, showcasing its strong reputation in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record in securities class actions to ensure effective legal representation, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
REGENXBIO Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO, alleging violations of federal securities laws from February 9, 2022, to January 27, 2026, seeking damages for investors, highlighting significant investor concerns regarding corporate transparency.
- False Statement Allegations: The complaint claims that REGENXBIO made materially misleading statements regarding the development of RGX-111 gene therapy, particularly that positive expectations about its clinical trial lacked a reasonable basis, potentially leading investors to misjudge the company's prospects.
- Investor Rights Protection: Affected investors have until April 14, 2026, to request to be appointed as lead plaintiff, indicating the potential impact of this case on investors and their opportunity to participate in the legal process, emphasizing the importance of legal recourse.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, showcasing its expertise in securities fraud class actions, which enhances investor confidence in the potential outcomes of the case.
See More
Regenxbio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data, leading to significant investor losses once the truth was revealed, indicating a pattern of false and misleading public statements throughout the class period.
- Market Reaction: Following the revelation of concealed negative information, investor losses surged, highlighting the company's major missteps in disclosure practices, which could lead to a trust crisis and impact future financing capabilities.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to join the lawsuit for potential recovery, underscoring the importance of legal avenues in protecting shareholder rights.
See More
REGENXBIO Class Action Lawsuit Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding the development of RGX-111 gene therapy, claiming positive biomarker and safety data while concealing material adverse facts about the therapy's efficacy and safety, resulting in investor losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in the field.
- Investor Selection Advice: The law firm advises investors to choose qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure optimal legal support and representation in the class action.
See More
Faruqi & Faruqi Encourages REGENXBIO Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against REGENXBIO, specifically targeting investors who purchased or acquired securities between February 9, 2022, and January 27, 2026, aiming to protect investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to investor advocacy.
- Class Action Reminder: The firm reminds investors that April 14, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against REGENXBIO, emphasizing the importance of timely action.
- Potential Impact Assessment: This legal action could negatively affect REGENXBIO's stock price, prompting investors to monitor developments closely to make informed investment decisions.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Choosing Legal Counsel: The firm emphasizes the importance of selecting qualified legal representation with a proven track record, noting that many firms issuing notices may lack the necessary experience and resources to effectively handle securities class actions.
- Case Background: The lawsuit alleges that defendants provided misleading information regarding REGENXBIO's RGX-111 gene therapy development, concealing adverse facts about its efficacy and safety, which resulted in investor losses when the truth emerged.
- Historical Achievements: In 2019, Rosen Law Firm secured over $438 million for investors and was ranked first by ISS Securities Class Action Services in 2017 for the number of settlements, showcasing its strong capabilities and influence in the securities litigation field.
See More
Notice of Class Action Lawsuit Against REGENXBIO Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that REGENXBIO misled investors regarding its RGX-111 gene therapy development, providing false and misleading information while claiming positive biomarker and safety data from ongoing Phase I/II studies.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company in 2017, showcasing its strong reputation in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record in securities class actions to ensure effective legal representation, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
REGENXBIO Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO, alleging violations of federal securities laws from February 9, 2022, to January 27, 2026, seeking damages for investors, highlighting significant investor concerns regarding corporate transparency.
- False Statement Allegations: The complaint claims that REGENXBIO made materially misleading statements regarding the development of RGX-111 gene therapy, particularly that positive expectations about its clinical trial lacked a reasonable basis, potentially leading investors to misjudge the company's prospects.
- Investor Rights Protection: Affected investors have until April 14, 2026, to request to be appointed as lead plaintiff, indicating the potential impact of this case on investors and their opportunity to participate in the legal process, emphasizing the importance of legal recourse.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, showcasing its expertise in securities fraud class actions, which enhances investor confidence in the potential outcomes of the case.
See More
